Maria Palasis, Ph.D., is an accomplished scientist, inventor, entrepreneur and healthcare industry leader who has led the development of multiple highly successful medical device and drug delivery systems. She is considered one of the pioneers of drug-eluting stents, currently over a ~$6B annual commercial market.
Dr. Palasis has served as Lyra Therapeutics’ President and Chief Executive Officer and a member of its board of directors since January 2015. Previously, she was the Executive Vice President and Chief Technology Officer from 2011 to 2015. Prior to Lyra Therapeutics, Dr. Palasis was President and CEO of both Arsenal Medical and its spin-out, 480 Biomedical. At Arsenal Medical and 480 Biomedical, she secured strategic partnerships with large medical device companies and was instrumental in leading the company from pre-clinical into clinical development on multiple programs. As an executive, she has led the raising of over $300M of private and public proceeds from investors and non-dilutive government and strategic funding.
From 1995 to 2008, Dr. Palasis served in senior leadership roles at Boston Scientific Corporation, Inc., where she spearheaded major strategic alliances with biotechnology and pharmaceutical companies, led due diligence on investments, and managed a portfolio of external biotechnology and medical device investments totaling $170M. She was an early member of the team that created the TAXUS® drug-eluting stent, the single most important revenue generator for the company at the time, a $3B annual product.
Dr. Palasis is an inventor on more than 120 issued and pending patents related to drug eluting medical implants and drug delivery systems. She was elected into the National Academy of Engineering in 2021 for outstanding contributions to the design of medical devices and drug delivery systems. Dr. Palasis serves on the Board of Directors of PanTher Therapeutics and is on the Advisory Board of MedExecWomen, a non-profit focused on empowering female executives in medical technology. She holds a B.S. and Ph.D. in Chemical Engineering from the University of Cincinnati and completed her postdoctoral fellowship in Molecular Biology at the University of Cincinnati School of Medicine.
What is Maria Palasis' net worth?
The estimated net worth of Maria Palasis is at least $208.38 thousand as of January 6th, 2026. Dr. Palasis owns 1,096,733 shares of Lyra Therapeutics stock worth more than $208,379 as of October 13th. This net worth estimate does not reflect any other assets that Dr. Palasis may own. Learn More about Maria Palasis' net worth.
How do I contact Maria Palasis?
Has Maria Palasis been buying or selling shares of Lyra Therapeutics?
Maria Palasis has not been actively trading shares of Lyra Therapeutics during the last ninety days. Most recently, Maria Palasis sold 1,702 shares of the business's stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $3.36, for a transaction totalling $5,718.72. Following the completion of the sale, the chief executive officer now directly owns 1,096,733 shares of the company's stock, valued at $3,685,022.88. Learn More on Maria Palasis' trading history.
Who are Lyra Therapeutics' active insiders?
Are insiders buying or selling shares of Lyra Therapeutics?
In the last year, insiders at the sold shares 8 times. They sold a total of 118,736 shares worth more than $535,086.61. The most recent insider tranaction occured on January, 6th when CFO Jason Cavalier sold 769 shares worth more than $2,583.84. Insiders at Lyra Therapeutics own 3.3% of the company.
Learn More about insider trades at Lyra Therapeutics. Information on this page was last updated on 1/6/2026.
